Results 91 to 100 of about 1,428 (167)

Discovery of Tofogliflozin, a Novel C‑Arylglucoside with an O‑Spiroketal Ring System, as a Highly Selective Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

, 2016
Inhibition of sodium glucose cotransporter 2 (SGLT2) has been proposed as a novel therapeutic approach to treat type 2 diabetes. In our efforts to discover novel inhibitors of SGLT2, we first generated a 3D pharmacophore model based on the superposition ...
Hiroharu Matsuoka (2044576), Koji Yamaguchi (93289), Masahiro Nishimoto (747024), Koo-Hyeon Ahn (2044600), Kazuharu Ozawa (2044570), Yoshihito Ohtake (1973821), Koji Takano (308233), Kyoko Takami (2044579), Tsutomu Sato (58517), Naoki Taka (2044585), Masayuki Suzuki (305112), Marina Yamaguchi (2044591), Keisuke Yamamoto (165942), Motohiro Kato (2044588), Sachiya Ikeda (2044582), Takamitsu Kobayashi (2044594), Masayuki Ohmori (2044573), Hitoshi Hagita (2044567), Kazumi Morikawa (2044597), Sang-Yong Yeu (1973830)   +19 more
core   +1 more source

Virtual screening of approved drugs nominates tofogliflozin for the SHP2 allosteric pocket

SHP2 supports oncogenic RAS–MAPK signaling, and ligands in its regulatory allosteric pocket can stabilize the autoinhibited state. Approved drugs were screened for an accessible probe of this pocket.
Osama Abdullatif
core   +1 more source

Nocturia and SGLT2 inhibitors: A review of pathophysiology, clinical evidence, and therapeutic implications

Continence
Background: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are widely used in patients with diabetes, heart failure, and chronic kidney disease, all of whom are at elevated risk for nocturia.
Matthew Antonellis, Robert Adler, Michael Kozlov, Jason Lazar, Jeffrey P. Weiss   +4 more
doaj   +1 more source

Cardioprotective Effects of Sodium-Glucose Cotransporter Subtype Inhibition on Ischemic and Pharmacological Preconditioning [PDF]

Cureus
Nagasaki University (長崎大学)博士(医学)Background: Sodium-glucose cotransporter (SGLT) 2 inhibitors partially inhibit SGLT1 expression; however, whether a clinical dose of SGLT2 inhibitor abrogates ischemic preconditioning (IPC) is unknown, and the ...
Egashira T, Ichinomiya T, Yokoyama A, Matsumoto S, Higashijima U, Sekino M, Murata H, Yoshitomi O, Sato S, Hara T.   +9 more
europepmc   +4 more sources

A retrospective study of seasonal variation in sodium-glucose co-transporter 2 inhibitor-related adverse events using the Japanese adverse drug event report database

Scientific Reports
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a class of drugs used in the clinical management of patients with type 2 diabetes, and their prescriptions have been increasing in recent years.
Kiyoka Matsumoto, Fumiya Goto, Mika Maezawa, Satoshi Nakao, Koumi Miyasaka, Sakiko Hirofuji, Kohei Shiota, Nanaka Ichihara, Moe Yamashita, Yuka Nokura, Tomofumi Yamazaki, Kana Sugishita, Hideyuki Tanaka, Hirofumi Tamaki, Motoyuki Ishiguro, Kazuhiro Iguchi, Mitsuhiro Nakamura   +16 more
doaj   +1 more source

Model-based meta-analysis of HbA1c reduction across SGLT2 inhibitors using dose adjusted by urinary glucose excretion

Scientific Reports
This study was aimed to evaluate whether the dose–response relationship of the sodium glucose co-transporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)—canagliflozin, dapagliflozin, empagliflozin, ipragliflozin ...
Hiromi Sato, Ayana Ishikawa, Hideki Yoshioka, Ryota Jin, Yamato Sano, Akihiro Hisaka   +5 more
doaj   +1 more source

What Does the Proinsulin/C-Peptide Ratio Reflect? [PDF]

Diabetes Obes Metab
Nakamura A, Miyamoto M, Kameda H, Cho KY, Okada K, Atsumi T.   +5 more
europepmc   +1 more source

Progranulin Deficiency Improves Metabolic Stress Yet Falls Short of Sodium-Glucose Cotransporter-2 Inhibition in Autophagy-Linked Renal Protection. [PDF]

Endocrinol Metab (Seoul)
Im SS.
europepmc   +1 more source

Bullous Pemphigoid Following IgG/IgA Pemphigus: Possible Involvement of SGLT2 and DPP-4 Inhibitors. [PDF]

Acta Derm Venereol
Ikeda A, Tani N, Ishii N, Koga H, Yoshida Y.   +4 more
europepmc   +1 more source

Effects of SGLT2 inhibitors on body composition and potential sarcopenia-related outcomes in type 2 diabetes mellitus: a network meta-analysis. [PDF]

Front Endocrinol (Lausanne)
Li X, Zhang Y, Wang L, Zhao Y.
europepmc   +1 more source